Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Retained Earnings of $2.2 billion for Q1 2026, up 4.89% year-over-year from $2.1 billion in Q1 2025, and up 7413316.67% quarter-over-quarter from $30000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Retained Earnings for 17 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 4.89% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (up 4.89% YoY), while the FY2025 annual figure was $30000.0, up 100.0% from the prior year.
- Retained Earnings advanced to $2.2 billion in Q1 2026 per LXRX's latest filing, from $30000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $2.2 billion in Q1 2026 and bottomed at -$2.0 billion in Q4 2024.
- Historically, Retained Earnings has averaged $336.7 million across 5 years, with a median of $30000.0 in 2025.
- On a YoY basis, Retained Earnings climbed as much as 17091540.0% in 2022 and fell as far as 30716680.0% in 2022.
- Lexicon Pharmaceuticals' Retained Earnings stood at $1.7 billion in 2022, then rose by 8.98% to $1.9 billion in 2023, then sank by 205.62% to -$2.0 billion in 2024, then soared by 100.0% to $30000.0 in 2025, then jumped by 7413316.67% to $2.2 billion in 2026.
- Business Quant data shows LXRX's Retained Earnings at $2.2 billion in Q1 2026, $30000.0 in Q4 2025, and $2.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 2.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Bn |
| Mar 31, 2026 | 2.22 Bn |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 2.13 Bn |
| Jun 30, 2025 | 2.12 Bn |
| Mar 31, 2025 | 2.12 Bn |
| Dec 31, 2024 | -1.97 Bn |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | -193,000.00 |
| Mar 31, 2024 | -50,000.00 |
| Dec 31, 2023 | 1.86 Bn |
| Sep 30, 2023 | 1.86 Bn |
| Jun 30, 2023 | -1.67 Bn |
| Mar 31, 2023 | -1.62 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | -491,000.00 |
| Jun 30, 2022 | -1.54 Bn |
| Mar 31, 2022 | -1.51 Bn |
| Dec 31, 2021 | -10,000.00 |
| Sep 30, 2021 | -6,000.00 |